Last year, the biologics sector managed single-digit growth in the United States, driven mainly by products indicated for oncology, diabetes and autoimmune disorders. Lurking on the horizon,

though, are challenges, such as pricing, competition and follow-on molecules. Access through your institution Buy or subscribe This is a preview of subscription content, access via your

institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this

article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in

Rev. Drug Discov._ 9, 427–428 (2010). Article  CAS  Google Scholar  * Pollack, A. FDA extends Avastin's use to breast cancer. _New York Times_ 23 February 2008

<http://www.nytimes.com/2008/02/23/business/23drug.html> Google Scholar  * Peterson, M. & Doherty, D. Roche may lose $1 billion a year on Avastin change. _Bloomberg

Businessweek_ 21 July 2010 <http://www.businessweek.com/news/2010–07–21/roche-may-lose-1-billion-a-year-on-avastinchange.html> Google Scholar  * Anonymous. Pink sheet–FDA will

revisit appropriate use of PFS endpoints at advisory committee. _Friends of Cancer Research Newsletter_, 2008

<http://www.focr.org/pink-sheet-fda-will-revisit-appropriate-use-of-pfs-endpoints-at-advisory-committee.html> * Krilov, L.R. et al. _Pediatrics_ 124, 1682–1684 (2009). Article

  Google Scholar  * Lowry, F. FDA panel nixes licensing request for motavizumab. _Medscape Medical News_ (2010). <http://www.medscape.com/viewarticle/722903>; June 3, 2010.

Google Scholar  * Lowy, I. et al. _N. Engl. J. Med._ 362, 197–205 (2010). Article  CAS  Google Scholar  * FDA approves a risk evaluation and mitigation strategy (REMS) to ensure the safe use

of Erythropoiesis-Stimulating Agents (ESAs). _US Department of Health & Human Services, US Food and Drug Administration_ 16 February 2010

<http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm200847.htm> * Unger, E.F., Thompson, A.M., Blank, M.J. & Temple, R. _N. Engl. J. Med._ 362, 189–192 (2010). Article  CAS

  Google Scholar  * <http://www.cms.gov/ESRDPayment/> * Information for Health care Professionals: Exantide (marketed as Byetta) 8.2008 update

<http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm>. * Parks, M. & Rosebraugh, C. _N. Engl. J. Med._ 362, 774–777

(2010). Article  CAS  Google Scholar  * Genovese, M.C. et al. _N. Engl. J. Med._ 353, 1114–1123 (2005). Article  CAS  Google Scholar  * Vincenti, F. et al. _N. Engl. J. Med._ 353, 770–781

(2005). Article  CAS  Google Scholar  * Cohen, J.A. et al. _N. Engl. J. Med._ 362, 402–415 (2010). Article  CAS  Google Scholar  * McHutchison, J.G. et al. _N. Engl. J. Med._ 360, 1827–1838

(2009). Article  CAS  Google Scholar  * Anonymous. In pivotal phase 3 studies, Merck's investigational medicine boceprevir helped majority of patients with chronic Hepatitis C genotype

1 infection achieve sustained virologic response, the primary endpoint of the studies. _Merck Newsroom_ 4 August 2010

<http://www.merck.com/newsroom/news-release-archive/research-and-development/2010_0804.html> * Colvin, H.C. & Mitchell, A.E. (eds.) _Hepatitis and Liver Cancer: A National

Strategy for Prevention and Control of Hepatitis B and C_ (The National Academies Press, 2010). Google Scholar  * Kim, J.J. & Goldie, S.J. _BMJ_ 339, b3884 (2009). Article  Google

Scholar  * Peres, J. _J. Natl. Cancer Inst._ 102, 838–840 (2010). Article  Google Scholar  * Kelley, R.K. & Venook, A.P. _N. Engl. J. Med._ 363, 596–598 (2010). Article  CAS  Google

Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Saurabh Aggarwal is a healthcare consultant based in New York., Saurabh Aggarwal Authors * Saurabh Aggarwal View

author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Saurabh Aggarwal. ETHICS DECLARATIONS COMPETING INTERESTS The author

declares no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Aggarwal, S. What's fueling the biotech engine—2009–2010.

_Nat Biotechnol_ 28, 1165–1171 (2010). https://doi.org/10.1038/nbt1110-1165 Download citation * Published: 05 November 2010 * Issue Date: November 2010 * DOI:

https://doi.org/10.1038/nbt1110-1165 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative